Mecain

Mepivacaine, the active ingredient in Mecain, is a local anesthetic presented as a sterile solution for epidural, intradermal and intrathecal use. It provides temporary loss of sensation for dental procedures, minor surgeries and obstetric analgesia.

GNH USA supplies Mecain as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mepivacaine is a local anesthetic used to achieve reversible loss of sensation in various clinical settings.

- Dental procedures: provides local anesthesia for tooth extractions, restorations and periodontal work. - Minor surgical procedures: enables short‑duration anesthesia for skin suturing, biopsies and minor excisions. - Epidural analgesia: offers regional anesthesia for labor and postoperative pain management.

Mepivacaine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Transient numbness at the injection site. - Mild tingling or burning sensation. - Injection site pain or bruising. - Temporary hypotension. - Bradycardia. - Dizziness or light‑headedness.

Serious or Rare Side Effects: - Seizures or convulsions. - Cardiac arrest or severe arrhythmias. - Anaphylactic or severe allergic reactions. - Methemoglobinemia. - Persistent neurologic deficits. - Respiratory depression.

When using Mecain, clinicians should observe several safety measures. - Allergy assessment: verify no known hypersensitivity to amide‑type local anesthetics. - Cardiovascular monitoring: observe heart rate and blood pressure during administration. - Hepatic impairment: adjust technique and dosage in patients with liver dysfunction. - Intravenous injection avoidance: aspirate before injection to prevent systemic toxicity. - Pregnancy considerations: use only when benefits outweigh potential risks. - Store at ambient temperature: keep in original container, protect from moisture and light.

Mepivacaine can interact with other medications, requiring careful management.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine, procainamide): may potentiate cardiotoxicity. - High‑dose beta‑blockers (e.g., propranolol): increase risk of severe bradycardia.

Moderate Interactions (Monitor Closely): - Concurrent use of other local anesthetics: cumulative toxicity risk. - CYP450 inhibitors (e.g., erythromycin, fluconazole): may raise plasma levels. - Diuretics (e.g., furosemide): can enhance hypotensive effects. - Central nervous system depressants (e.g., benzodiazepines): may augment sedation.